Process for the preparation of amorphous form of neutral esomeprazole
A process for preparing neutral esomeprazole in an amorphous form is provided comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) neutralizing the solution with a neutralization agent to provide a neutralized solution; (c) contacting the neutralized solution with an extracting solvent; and (d) recovering the neutral esomeprazole in an amorphous form.
1 . A process for preparing neutral esomeprazole in an amorphous form, the process comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) neutralizing the solution with a neutralization agent to provide a neutralized solution; (c) contacting the neutralized solution with an extracting solvent; and (d) recovering the neutral esomeprazole in an amorphous form.
2 . The process of claim 1 , wherein the salt of esomeprazole is esomeprazole sodium or esomeprazole potassium.
3 . The process of claim 1 , wherein step (a) comprises dissolving esomeprazole sodium or esomeprazole potassium in water.
4 . The process of claim 1 , wherein the neutralization agent is an acid-base salt.
5 . The process of claim 4 , wherein the acid-base salt is selected from the group consisting of ammonium acetate, ammonium chloride, ammonium bromide, pyridine acetate, triethylamine acetate and mixtures thereof.
6 . The process of claim 1 , wherein the neutralization agent is a suitable acid.
7 . The process of claim 6 , wherein the suitable acid is selected from the group consisting of hydrochloric acid, sulfonic acid, sulfuric acid, sulfurous acid, phosphoric acid, carbonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, maleic acid, oxalic acid, chloroacetic acid, benzoic acid and mixtures thereof.
8 . The process of claim 1 , wherein the extracting solvent is a chlorinated solvent.
9 . The process of claim 1 , wherein the extracting solvent is a chlorinated solvent selected from the group consisting of chloroform, carbon tetrachloride, perchloroethylene, methylene chloride and mixtures thereof.
10 . The process of claim 1 , further comprising removing the extracting solvent from the solution to form a solid residue.
11 . The process of claim 10 , wherein the extracting solvent is removed by heating at an elevated temperature under reduced pressure.
12 . The process of claim 10 , further comprising adding an aliphatic hydrocarbon solvent to the solid residue and filtering the neutral esomeprazole in an amorphous form.
13 . The process of claim 12 , wherein the aliphatic hydrocarbon solvent is selected from the group consisting of n-hexane, isooctane, n-heptane and mixtures thereof.
14 . An amorphous form of neutral esomeprazole prepared by the process of claim 1 .
15 . The amorphous form of neutral esomeprazole of claim 14 , further characterized by having an X-ray diffraction pattern substantially in accordance with FIG. 1 .
16 . A pharmaceutical composition comprising a therapeutically effective amount of the amorphous form of neutral esomeprazole of claim 14 and one or more pharmaceutically acceptable carriers.
17 . The pharmaceutical composition of claim 16 , in the form of a solid.
18 . A method for reducing gastric acid secretion in a subject which comprises administering to the subject an amount of the amorphous form of neutral esomeprazole of claim 14 in solid form and effective to reduce gastric acid secretion by the subject.
19 . A process for preparing neutral esomeprazole in an amorphous form, the process comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) adding an acid-base salt to the solution; (c) contacting the solution of step (b) with a chlorinated solvent; and (d) recovering the neutral esomeprazole in an amorphous form from the solution of step (c).
20 . The process of claim 19 , wherein the acid-base salt is selected from the group consisting of ammonium acetate, ammonium chloride, ammonium bromide, pyridine acetate, triethylamine acetate and mixtures thereof.
21 . The process of claim 19 , wherein the chlorinated solvent selected from the group consisting of chloroform, carbon tetrachloride, perchloroethylene, methylene chloride and mixtures thereof.
22 . The process of claim 19 , wherein the step (d) comprises heating the solution of step (c) to a temperature sufficient to substantially remove the chlorinated solvent and obtain a solid residue; adding a suitable solvent to the solid residue followed by filtration to provide the neutral esomeprazole in an amorphous form.
23 . The process of claim 22 , wherein the solution is heated to a temperature of about 20° C. to about 45° C.
24 . The process of claim 22 , wherein the suitable solvent is selected from the group consisting of n-hexane, isooctane, n-heptane and mixtures thereof.